Eye Therapies LLC

Presbyopia Therapies LLC

Other

Lenz Therapeutics, Inc.

Alpha Synergy Development, Inc.

Ocularis Pharma, Inc.

Lenz Therapeutics Operations, Inc.

Ontogenesis, LLC

Premium Ocular Solutions Llc.

Ps Therapy Inc.

Health Performance, Inc.

Kerus Medical Systems

Gnt LLC

Glaucoma & Nasal Therapies LLC

Retinal Therapies, LLC

Gerald H Horn

Lee Nordan

Kenneth G Spears

Osvaldo Jorge Lopez

Gene W Zdenek

The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.

Compositions, methods, and systems for treating presbyopia

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.

Vasoconstriction compositions and methods of use

The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH from about 4.0 to about 7.5.

The present invention is directed to derivatives of aceclidine. The present invention is further directed to ophthalmological compositions comprising a therapeutically effective amount of a compound of the present invention and one or more pharmaceutically acceptable excipients. The present invention is further directed to a methods of treating presbyopia or glaucoma or reducing hyperemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.

Aceclidine derivatives, compositions thereof and methods of use thereof

The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.

Methods for improving vision

The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.

Compositions and methods for storage stable ophthalmic drugs

The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.

Compositions and methods for the treatment of presbyopia

The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

Multi-tyrosine kinase inhibitors derivatives and methods of use

The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

Drug vehicle compositions and methods of use thereof

The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective &#x3b1;-2 adrenergic receptor agonist.

Methods for the treatment of myopia

The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.

Growing community of inventors

Peoria, IL, United States of America

Gerald H Horn